Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · market

UniQure tumbles with latest data for Huntington's gene therapy

29 September 2026 · By · Wire by Fusion42

Published

29 September 2026

Topic

market

◆ Sectors

BiotechDrug Discovery

◆ Geography

United States

◆ Source

Read at biopharmadive.com →

◆ Verified

Fusion42 · 29 September 2026 · Fusion42 review

UniQure's stock dropped following the release of four-year durability data for its Huntington's disease gene therapy AMT-130, which fell short of investor expectations related to potential approval.

This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery, and 2 sources have reported it.

◆ ◆ The Wire takeaway

You must reassess your gene therapy durability benchmarks in Huntington’s disease as investor patience tightens and approval pathways may shift. Falling short here signals higher scrutiny ahead and a need to strengthen your clinical durability data.

◆ Coverage

2 sources · 29 Sep 2026

◆ Related on Wire

◆ Topics

BiotechDrug Discoverygene-therapyhuntingtons-diseaseclinical-trialsdrug-approvalbiotech